Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.On December 13th, Jiangsu Securities Regulatory Bureau issued an announcement that Yan Zhen had privately accepted the entrustment of customers to buy and sell securities during his tenure in the securities business department of Xuzhou Jianguo West Road of CITIC Securities (formerly known as the securities business department of Xuzhou Jiefang South Road of CITIC Securities). In violation of regulations, she was supervised to issue a warning letter and recorded it in the integrity file of the securities and futures market.Zhuhai Guanyu: It was selected as the designated supplier of low-voltage lithium batteries for its 12V cars after being notified by domestic car companies. Zhuhai Guanyu announced that the company was recently notified by a domestic car company and was selected as the designated supplier of low-voltage lithium batteries for its 12V cars. This appointment will help to enhance the company's competitiveness and sustainable development ability in this field, and lay the foundation for future market share enhancement. At present, the company has been recognized by many well-known car companies, such as SAIC, Zhiji, Jaguar Land Rover, Stellantis, GM, etc., and has obtained a number of vehicle project designation letters. However, the fixed-point notice is not the final supply agreement, and the project needs to go through many links from fixed-point to mass production, so it is uncertain whether the order can be obtained in the end.
Keheng shares: signed a cooperation framework agreement with Gree supply chain, and Keheng shares announced that the company and its wholly-owned subsidiaries Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng and Haoneng Technology signed a cooperation framework agreement with Gree supply chain. Gree supply chain granted Jiangmen Keheng, Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng and Haoneng Technology a total of 650 million yuan in raw material procurement business.Jinghe Jicheng: Shareholder Lijing Venture Capital intends to transfer 1.50% shares of the company by inquiry, and Jinghe Jicheng announced that shareholder Lijing Venture Capital intends to transfer 30.092 million shares of the company by inquiry transfer, accounting for 1.50% of the company's total share capital.COMEX silver fell 2.00% in the day and is now quoted at $30.99 per ounce. COMEX silver fell to $31 per ounce, down 1.97% in the day.
BYD Lian Yubo: It is estimated that BYD will sell 4.25 million vehicles in the whole year. On December 13th, BYD's chief scientist Lian Yubo said: "Up to now, BYD has sold more than 10 million new energy vehicles. By the end of this month, we can probably achieve the annual sales of 4.25 million vehicles. " He also mentioned: "There are still some challenges in industrial development. For example, the overall anti-risk ability of our industrial chain needs to be improved, and there are still breakthroughs in chips, operating technologies, industrial software and nuclear materials. We still need to strengthen research and achieve complete autonomy and controllability."Kangxinuo Bio: Dong Xiaoman was appointed as the new general partner of Shanghai Qianxizhi, and Kangxinuo Bio (06185) issued an announcement. On December 13, 2024, Dr. Zhu informed the board of directors that in view of the need for sufficient time to manage the employee stock ownership platform, all the partners of the employee stock ownership platform unanimously decided to appoint Well Lee as the new general partner of Shanghai Qianxiyi and Shanghai Qianxirui respectively, and Dong Xiaoman as the new general partner of Shanghai Qianxizhi. Therefore, Dr. Zhu is no longer the general partner of the employee stock ownership platform and no longer has the right to exercise the voting rights of the shares held by the employee stock ownership platform.Huawang Technology: Zhang Yancheng, the director, plans to reduce the company's shares by no more than 0.3443%. Huawang Technology announced that Zhang Yancheng, the company's director and senior manager, plans to reduce the company's shares by no more than 1.6 million shares through centralized bidding on the Shanghai Stock Exchange within three months after the announcement date, accounting for 0.3443% of the company's total share capital. The reduction price will be determined according to the market price. Zhang Yancheng currently holds 6,671,700 shares of the company, accounting for 1.4357% of the company's total share capital.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide